Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.
Receipt of cytotoxic chemotherapy in the 3 months before testing positive for SARS-CoV-2 infection is not associated with an increased risk for severe COVID-19 symptoms, US research suggests.
A quick-reference guide to the CheckMate trials investigating the anti-PD-1 agent nivolumab, as monotherapy or in combination with the anti-CTLA-4 agent ipilimumab, in patients with renal cell carcinoma.
Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.
22-09-2020 | ESMO 2020 | Conference coverage | Video
Fabrice André presents the overall survival data from the SOLAR-1 trial of alpelisib in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, and outlines the next steps for the further development of alpelisib and other PI3K inhibitors in this setting.
Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.
The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.
21-09-2020 | ESMO 2020 | Conference coverage | Video
Masahiro Tsuboi discusses the clinical implications of the primary and CNS analyses of the ADAURA trial of adjuvant osimertinib in EGFR-mutated non-small-cell lung cancer and outlines the key next steps.
20-09-2020 | ESMO 2020 | Conference coverage | Video
Christopher Sweeney highlights the key questions arising from the primary endpoint analysis of the IPATential150 study of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
